Literature DB >> 26614916

One-Stage Revision for Infected Total Hip Arthroplasty.

Akos Zahar1, Thorsten A Gehrke2.   

Abstract

Prosthetic joint infection (PJI) is a challenging complication following total hip arthroplasty (THA). Two-stage exchange arthroplasty is preferred for treating chronic PJI of THA, although specialized centers have reported comparable outcomes with protocol-based, 1-stage exchange arthroplasty. A main requirement is presurgical determination of the infecting organism's sensitivity. The therapeutic goal is control of the infection and maintenance of joint function. It offers advantages, including a single operative procedure, fewer antibiotics, and reduced hospitalization time and relative overall costs.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cemented revision; Complication of total hip arthroplasty; One-stage septic exchange; Posterior approach; Prosthetic joint infection (PJI)

Mesh:

Substances:

Year:  2016        PMID: 26614916     DOI: 10.1016/j.ocl.2015.08.004

Source DB:  PubMed          Journal:  Orthop Clin North Am        ISSN: 0030-5898            Impact factor:   2.472


  12 in total

1.  CORR Insights®: What are the Factors Associated With Re-revision After One-stage Revision for Periprosthetic Joint Infection of the Hip? A Case-control Study.

Authors:  Hany Bedair
Journal:  Clin Orthop Relat Res       Date:  2019-10       Impact factor: 4.176

Review 2.  Treatment patterns and failure rates associated with prosthetic joint infection in unicompartmental knee arthroplasty: A systematic review.

Authors:  Joseph P Barbera; Ryan C Xiao; Christine S Williams; Jashvant Poeran; Calin S Moucha; Darwin D Chen; Brett L Hayden
Journal:  J Orthop       Date:  2022-09-14

3.  Blood loss and allogeneic transfusion for surgical treatment of periprosthetic joint infection: a comparison of one- vs. two-stage exchange total hip arthroplasty.

Authors:  Ahmad Shoib Sharqzad; Camila Cavalheiro; Akos Zahar; Christian Lausmann; Thorsten Gehrke; Daniel Kendoff; Javad Parvizi; Mustafa Citak
Journal:  Int Orthop       Date:  2018-09-05       Impact factor: 3.075

4.  Comparison of cultures and 16S rRNA sequencing for identification of bacteria in two-stage revision arthroplasties: preliminary report.

Authors:  Przemysław Bereza; Alicja Ekiel; Aleksandra Auguściak-Duma; Małgorzata Aptekorz; Iwona Wilk; Damian Kusz; Piotr Wojciechowski; Aleksander L Sieroń; Gayane Martirosian
Journal:  BMC Musculoskelet Disord       Date:  2016-03-25       Impact factor: 2.362

Review 5.  One-stage Exchange Arthroplasty for Periprosthetic Hip and Knee Joint Infections.

Authors:  Manny Nguyen; Mohamed Sukeik; Akos Zahar; Ikram Nizam; Fares Sami Haddad
Journal:  Open Orthop J       Date:  2016-11-30

6.  Management of the Infected Total Hip Arthroplasty.

Authors:  D'jon Lopez; Isabel Leach; Elinor Moore; Alan R Norrish
Journal:  Indian J Orthop       Date:  2017 Jul-Aug       Impact factor: 1.251

7.  Septic arthritis following femoral neck fracture: A case report.

Authors:  Chulin Chewakidakarn; Anuchit Nawatthakul; Methasit Suksintharanon; Varah Yuenyongviwat
Journal:  Int J Surg Case Rep       Date:  2019-04-04

8.  What Is the Mid-term Survivorship of Infected Rotating-hinge Implants Treated with One-stage-exchange?

Authors:  Malte Ohlmeier; Fadi Alrustom; Mustafa Citak; Jochen Salber; Thorsten Gehrke; Jannik Frings
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.176

9.  A Low Percentage of Patients Satisfy Typical Indications for Single-stage Exchange Arthroplasty for Chronic Periprosthetic Joint Infection.

Authors:  M E Dombrowski; A E Wilson; R A Wawrose; M J O'Malley; K L Urish; B A Klatt
Journal:  Clin Orthop Relat Res       Date:  2020-08       Impact factor: 4.755

10.  The use of augmented antibiotic-loaded cement spacer in periprosthetic joint infection patients with acetabular bone defect.

Authors:  Jun Fu; Yi Xiang; Ming Ni; Jiying Chen; Xiang Li; Baozhan Yu; Kan Liu; Yonggang Zhou; Libo Hao
Journal:  J Orthop Surg Res       Date:  2020-10-01       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.